Abstract
Background and Objectives With the increasing need for clinicians to develop novel treatment strategies for the treatment of CVDs, the future lies in developing personalized nutrient recommendations based on an individual’s needs. CoQ10, a key component of the mitochondrial electron transport chain, has emerged as a potential ally with proven cardioprotective effects. This study investigates the efficacy of Coenzyme Q10 (CoQ10) nutrient supplementation in improving mitochondrial function, systolic performance and other parameters in patients with cardiovascular diseases (CVDs).
Methods A systematic review and meta-analysis included data from PubMed, Embase, and the Cochrane Library up to January 2024. Inclusion criteria were randomized controlled trials (RCTs) involving adults with CVDs, comparing CoQ10 with placebo or standard care. Data extraction and quality assessment were performed using PRISMA guidelines, the Cochrane Collaboration’s RoB2 tool, AMSTAR 2, and GRADE. Primary outcome: mitochondrial function (ATP production, respiratory capacity). Secondary outcome: systolic function (ejection fraction).
Findings From initial reference list of 46 selected studies, 22 were extracted presenting the encompassing a total sum of 11,372 subjects that were included in the meta-analysis with a total follow-up time ranging from 2 to 144 months (12 years). The results revealed that CoQ10 supplementation significantly improved ejection fraction (mean difference: 5.6%, 95% CI: 3.2% to 8.0%, p<0.001, I²=25%). The I² statistic for ejection fraction was 25%, indicating low heterogeneity among the studies included in the meta-analysis. Mitochondrial function showed increased ATP production (SMD: 0.82, 95% CI: 0.60 to 1.04, p<0.001, I²=30%) and enhanced respiratory capacity (SMD: 0.75, 95% CI: 0.53 to 0.97, p<0.001, I²=28%). The I² statistics for ATP production and mitochondrial respiratory capacity were 30% and 28%, respectively, suggesting low to moderate heterogeneity among the included studies. Sensitivity analyses confirmed the robustness of the results, with consistent effect sizes and confidence intervals across both fixed-effect and random-effects models, and no significant changes upon excluding high-risk studies. Publication bias was low, as indicated by funnel plots and Egger’s test (p=0.12).
Limitations Larger-scale RCTs are needed to confirm findings and determine the optimal dosage and duration of CoQ10 therapy.
Conclusion CoQ10 has demonstrated to improve mitochondrial function, systolic performance, and other important cardiovascular health parameters in CVD patients. The evidence here presented strongly supports clinicians in the prescription of CoQ10 supplementation due to its proven efficacy in improving treatment outcomes and mitochondrial function in patients with CVDs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosure: The research detailed in the manuscript was conducted without any relationship to industry or conflicts of interest. Funding for the study was provided independently, ensuring an unbiased and objective approach. The study was conceived, designed, and executed independently, covering all aspects of the research.
As the study did not involve any human or animal subjects, there was no need to seek ethical approval. The content presented in the manuscript is entirely original and has not been submitted or considered for publication elsewhere. Full accountability for the accuracy and integrity of the work is accepted, ensuring that any questions related to the study will be appropriately addressed and resolved.
added new references, revised statistics, corrected grammar and other structure minor issues
Data Availability
All data produced in the present study are available upon reasonable request to the authors
